{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:05:49Z","timestamp":1782975949667,"version":"3.54.5"},"reference-count":32,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Women's Health"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>In 2005, the Food and Drug Administration (FDA) issued a decision memorandum regarding nonsteroidal anti-inflammatory drugs (NSAIDs). The memorandum recommended the withdrawal of certain NSAIDs due to potential cardiovascular adverse effects. It highlighted the issue of cardiovascular risk associated with NSAIDs as a class. The NSAID medication guide includes a wide range of adverse drug reactions (ADRs), such as increased blood pressure, liver failure, allergic reactions, heart attack, and intestinal bleeding. Although both sexes have an increased risk of ADRs with NSAID use, females have a greater risk than males due to differences in pharmacodynamics and higher medication concentrations (mg\/kg). In particular, females with high blood pressure, coronary heart, kidney, and liver disease are at an additional risk of harm from NSAID ADRs. This study quantifies sex-specific differences and other factors associated with prescription NSAID use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>The data for this study were obtained from the National Health and Nutrition Examination Survey (NHANES), a complex survey conducted by the Centers for Disease Control and Prevention (CDC) in two-year cycles. A survey-weighted logistic regression model was utilized to investigate potential sex differences with prescription NSAIDs in the context of other factors, including kidney disease, hypertension, liver disease, insurance status, coronary heart disease, and age, within the 2011\u20132018 NHANES survey data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Females reported a slightly higher percentage of high blood pressure and kidney disease than males, while males reported a slightly higher percentage of coronary heart and liver disease than females. Last, the model indicated that females were 58% more likely to have used a prescription NSAID than males.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The results confirm that women and people with medical conditions, who would potentially suffer greater harm from NSAID ADRs, are more likely to use a prescription NSAID than individuals without these conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jwh.2023.1039","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T07:52:30Z","timestamp":1713426750000},"page":"901-907","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying Vulnerabilities to NSAID Adverse Events in the U.S. Population: An Analysis of Preexisting Conditions and Sex"],"prefix":"10.1177","volume":"33","author":[{"given":"Paul","family":"Rogers","sequence":"first","affiliation":[{"name":"National Center for Toxicological Research, Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, Jefferson, Arkansas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[{"name":"National Center for Toxicological Research, Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, Jefferson, Arkansas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Lu","sequence":"additional","affiliation":[{"name":"National Center for Toxicological Research, Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, Jefferson, Arkansas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Lyn-Cook","sequence":"additional","affiliation":[{"name":"National Center for Toxicological Research, Division of Biochemical Toxicology, U.S. Food and Drug Administration, Jefferson, Arkansas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1155\/1999\/361651"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.10.001"},{"key":"e_1_3_8_4_2","unstructured":"Jenkins J Seligman P. Decision Memo - Analysis and Recommendations for Agency Action - COX-2 Selective and Non-selective NSAIDs. FDA; Published April 2005. Available from: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/cox-2-selective-includes-bextra-celebrex-and-vioxx-and-non-selective-non-steroidal-anti-inflammatory [Last accessed: April10 2023]."},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/J354v19n04_15"},{"issue":"12","key":"e_1_3_8_6_2","first-page":"HS5","article-title":"Adverse events associated with NSAIDs","volume":"33","author":"Hawboldt J","year":"2008","unstructured":"Hawboldt J. Adverse events associated with NSAIDs. US Pharmacist, 2008; 33(12):HS5\u2013HS13.","journal-title":"US Pharmacist"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.755"},{"key":"e_1_3_8_8_2","unstructured":"U.S. Food and Drug Administration. Medication guide for non-steroidal anti-inflammatory drugs (NSAIDs). 2007. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/018766s015MedGuide.pdf [Last accessed: 17April 2023]."},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1557(199912)8:7<501::AID-PDS454>3.0.CO;2-Y"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7742(08)00001-9"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.19.2204"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2004.00224.x"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127009803801103"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.0000035856.77718.da"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.110454"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.3.571"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-30726-3_20"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C418"},{"issue":"12","key":"e_1_3_8_19_2","article-title":"Gender bias in the clinical evaluation of drugs","volume":"29","author":"Benjeaa Y","year":"2020","unstructured":"Benjeaa Y, , Geysels Y. Gender bias in the clinical evaluation of drugs. Applied Clinical Trials, 2020; 29(12).","journal-title":"Applied Clinical Trials"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071441"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2016-000550"},{"issue":"190","key":"e_1_3_8_22_2","first-page":"1","article-title":"National Health and Nutrition Examination Survey, 2015-2018: Sample Design and Estimation Procedures","volume":"184","author":"Chen TC","year":"2020","unstructured":"Chen TC, , Clark J, , Riddles MK, et al. National Health and Nutrition Examination Survey, 2015-2018: Sample Design and Estimation Procedures. Vital Health Stat 1, 2020; 184(190):1\u201336.","journal-title":"Vital Health Stat 1"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1454"},{"issue":"3","key":"e_1_3_8_24_2","first-page":"24","article-title":"NSAIDs: Balancing the risks and benefits","volume":"41","author":"Gorczyca P","year":"2016","unstructured":"Gorczyca P, , Manniello M, , Pisano M, et al. NSAIDs: Balancing the risks and benefits. US Pharm, 2016; 41(3):24\u201326.","journal-title":"US Pharm"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.12090"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-20730-3_14"},{"key":"e_1_3_8_28_2","volume-title":"Real World Health Care Data Analysis: Causal Methods and Implementation Using SAS","author":"Faries D","year":"2020","unstructured":"Faries D, , Zhang X, , Kadziola Z, et al. Real World Health Care Data Analysis: Causal Methods and Implementation Using SAS. SAS Institute Inc: Cary, NC; 2020."},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezy167"},{"key":"e_1_3_8_30_2","unstructured":"U.S. Food and Drug Administration. FDA has reviewed possible risks of pain medicine use during pregnancy. 2015. Available from: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/nonsteroidal-anti-inflammatory-drugs-nsaids-drug-safety-communication-avoid-use-nsaids-pregnancy-20#:\u223c:text=These%20labels%20already%20warn%20to professional%20before%20using%20these%20medicines [Last accessed: 04 April]."},{"key":"e_1_3_8_31_2","unstructured":"U.S. Food and Drug Administration. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. 2020. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic [Last accessed: 21August 2023]."},{"issue":"9","key":"e_1_3_8_32_2","first-page":"24","article-title":"Recognizing the risks of chronic nonsteroidal anti-inflammatory drug use in older adults","volume":"18","author":"Marcum ZA","year":"2010","unstructured":"Marcum ZA, , Hanlon JT. Recognizing the risks of chronic nonsteroidal anti-inflammatory drug use in older adults. Ann Longterm Care, 2010; 18(9):24\u201327.","journal-title":"Ann Longterm Care"},{"issue":"14","key":"e_1_3_8_33_2","first-page":"s267","article-title":"Quantifying the impact of NSAID-associated adverse events","volume":"19","author":"Fine M","year":"2013","unstructured":"Fine M. Quantifying the impact of NSAID-associated adverse events. Am J Manag Care, 2013; 19(14 Suppl):s267\u201372.","journal-title":"Am J Manag Care"}],"container-title":["Journal of Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jwh.2023.1039","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2023.1039","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2023.1039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:23:25Z","timestamp":1782973405000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jwh.2023.1039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1089\/jwh.2023.1039"],"URL":"https:\/\/doi.org\/10.1089\/jwh.2023.1039","relation":{},"ISSN":["1540-9996","1931-843X"],"issn-type":[{"value":"1540-9996","type":"print"},{"value":"1931-843X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}